
Commentary|Articles|August 8, 2025
Medicaid Cuts Have Far-Reaching Consequences in Women's Health: Alina Salganicoff, PhD
Author(s)Julia Bonavitacola, Alina Salganicoff, PhD
Alina Salganicoff, PhD, discusses the immediate effects of the budget cuts to Medicaid as it pertains to women's health across the country.
Advertisement
Advertisement
The budget bill crafted by Republican lawmakers and dubbed the One Big Beautiful Bill Act contained many changes in funding for health care services, including reductions in funding for Medicaid and the elimination of funding for Planned Parenthood, which could have sizeable effects in rural and women's health. Alina Salganicoff, PhD, senior vice president and director for women's health policy at KFF, spoke with The American Journal of Managed Care® about what these changes in the budget bill can mean for health care across the country.
Related to this article

Employer diabetes guide; Camden psychedelic therapy input; CRC after EMR; rural HFrEF care; JAMA obesity report.

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

Pimicotinib, a once-daily oral CSF-1R inhibitor, is now FDA approved for adults with TGCT for whom surgery may worsen function or cause severe morbidity.

Pooled real-world data show an 88% response rate with brexu-cel in relapsed mantle cell lymphoma (MCL), but cost and QOL data are scarce.

Faculty say heart failure patients miss iron deficiency care when no one owns it; pharmacist-led workflows may help close the gap.

The FDA approved cemdisiran (Livsayis; Regeneron), a subcutaneous siRNA dosed every 3 months, for AChR-positive generalized myasthenia gravis.
Advertisement
Advertisement


